Status:
ENROLLING_BY_INVITATION
Natural Matrix Protein
Lead Sponsor:
Hospital for Special Surgery, New York
Conditions:
Degenerative Lumbar Spinal Conditions
Eligibility:
All Genders
18+ years
Brief Summary
This clinical study is a non-randomized, consecutive, single-center, retrospective-prospective investigation of patients who received NMP bioimplant (Induce Biologics, Tampa, FL) in lumbar spinal fusi...
Detailed Description
Retrospective Data Collection: Patient data was collected into a data sheet to collect specific elements that relate to safety and efficacy of the procedure utilizing this specific device system. The...
Eligibility Criteria
Inclusion
- Patients experiencing symptomatic lumbar degenerative disc disease who failed conservative management at up to four vertebral levels between L1-S1 between February 2024 and December 2024.
- 2\. Adult patients (≥ 18 years old) who underwent lumbar fusion with an NMP graft and interbody cage
- \-
Exclusion
- Previous lumbar fusion attempts at the level of surgery (adjacent lumbar levels are acceptable) 2. Active Malignancy 3. Concurrently under chemotherapy 4. Active infection at time of surgery 5. Mentally compromised 6. Trauma to the operated region
- \-
Key Trial Info
Start Date :
March 18 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 17 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07217964
Start Date
March 18 2025
End Date
September 17 2027
Last Update
October 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital for Special Surgery
New York, New York, United States, 10021